Sign in

SER on NYSE

Serina Therapeutics, Inc.

In its 2026 annual report the company says: “We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications.”3 It is headquartered in Huntsville, Alabama.1 Its shares trade on NYSE under the symbol SER.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with CNBX Pharmaceuticals Inc., SOLIGENIX, INC. or BullFrog AI Holdings, Inc., or pick any stock.

  • TickerSER on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHuntsville, Alabama1
  • Incorporated inAL2
  • Business address601 Genome Way, Suite 2001, Huntsville, Al 358062
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).The Company’s proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline) and is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via easy-to-administer, long-acting subcutaneous injection.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-18478.5%Operating margin4
-14755.4%Net margin4
132.1%Revenue growth, 20254
-$18.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$13.2M
  • Income tax0¢$18.0K

Out of $130.0K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$130.0K in 2025−92% since 2019
0$1.0M$2.0M$3.0M$4.0M2019: $1.7M$1.7M20192020: $361.0K$361.0K2020−79%2021: $144.0K$144.0K2021−60%2022: $34.0K$34.0K2022−76%2023: $3.2M$3.2M2023+9174%2024: $56.0K$56.0K2024−98%2025: $130.0K$130.0K2025+132%
Gross profit5678$102.0K in 2023−93% since 2019
0$500.0K$1.0M$1.5M2019: $1.5M$1.5M20192020: $335.0K$335.0K2020−77%2021: $125.0K$125.0K2021−63%2022: $21.0K$21.0K2022−83%2023: $102.0K$102.0K2023+386%
Operating income567894-$24.0M in 2025+91% since 2019
-$30.0M-$20.0M-$10.0M02019: -$12.6M-$12.6M20192020: -$10.1M-$10.1M2020−20%2021: -$7.9M-$7.9M2021−21%2022: -$7.0M-$7.0M2022−12%2023: -$3.1M-$3.1M2023−55%2024: -$17.0M-$17.0M2024+445%2025: -$24.0M-$24.0M2025+41%
Net income567894-$19.2M in 2025+58% since 2019
-$20.0M-$10.0M0$10.0M2019: -$12.2M-$12.2M20192020: -$10.9M-$10.9M2020−11%2021: -$8.7M-$8.7M2021−20%2022: -$10.5M-$10.5M2022+21%2023: $5.3M$5.3M20232024: -$11.1M-$11.1M20242025: -$19.2M-$19.2M2025+72%
Fiscal year2019202020212022202320242025
Revenue$1.7M5$361.0K6$144.0K7$34.0K8$3.2M9$56.0K4$130.0K4
Cost of revenue$244.0K5$26.0K6$19.0K7$13.0K8$40.0K8
Gross profit$1.5M5$335.0K6$125.0K7$21.0K8$102.0K8
Research and development$5.9M5$3.7M6$1.5M7$1.0M8$2.4M9$7.5M4$13.2M4
Operating expenses$8.2M7$7.0M8$6.3M9$17.1M4$24.2M4
Operating income-$12.6M5-$10.1M6-$7.9M7-$7.0M8-$3.1M9-$17.0M4-$24.0M4
Interest$1.1M7$3.3M8$4.9M8
Income before tax$8.7M7$10.5M8$5.3M9-$11.2M4-$19.2M4
Income tax$148.0K5-$150.0K6$09$04$18.0K4
Net income-$12.2M5-$10.9M6-$8.7M7-$10.5M8$5.3M9-$11.1M4-$19.2M4
Earnings per share-$0.237-$9.708$2.369-$1.514-$1.914
Earnings per share (diluted)-$9.708$0.739-$1.514-$1.914
Shares (weighted, basic)37.9M shares71.1K shares82.2M shares97.4M shares410.2M shares4
Shares (weighted, diluted)1.1K shares87.4M shares97.4M shares410.2M shares4

Compare Serina Therapeutics, Inc. with another company

Corporate structure

Serina Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Serina Therapeutics, Inc.

  • Serina Therapeutics, Inc. Huntsville, Alabama

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Serina Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$993.0K4 Dec 31, 2025$1.1M4 Dec 31, 2024−9.9%
Accumulated depreciation$528.0K4 Dec 31, 2025$601.0K4 Dec 31, 2024−12.1%
Property and equipment, net$465.0K4 Dec 31, 2025$501.0K4 Dec 31, 2024−7.2%
Finance-lease assets$04 Dec 31, 2025$86.0K4 Dec 31, 2024−100.0%
Operating-lease assets (leased space)$377.0K4 Dec 31, 2025$461.0K4 Dec 31, 2024−18.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.1M4 Dec 31, 2025$3.7M4 Dec 31, 2024−16.8%

Properties, in its own words

Our principal place of business is located in Huntsville, Alabama where we lease approximately 7,600 square feet of office and laboratory space. Our office space lease expires on October 31, 2028, with options to renew, and our laboratory space lease expires on January 31, 2028. We believe that our existing facilities are adequate to meet our current needs, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms as needed.

Item 2 of the 10-K filed Mar 25, 2026.3

Leadership

Who has led Serina Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven A. Ledger2024–now

Chief financial officer

  1. Russell Skibsted2018–2019
  2. Andrea Eun Jae Park2020–2021
  3. Gregory S. Curhan2024–now

Chief operating officer

  1. Nafees Naseer Malik2018–2021
  2. Tacey Viegas2024
20202025
Board members and other officers (21)

Former names

  • AgeX Therapeutics, Inc.Jul 10, 2017 to Apr 1, 20242

Timeline

  1. Oct 9, 20268-K Bylaws or fiscal year changed38
  2. Sep 9, 20268-K Other events39
  3. Aug 27, 20268-K Entered a material agreement; Unregistered sale of shares40
  4. Aug 13, 20268-K Results of operations41
  5. Jul 23, 20268-K Executive or director change42
  6. Jul 22, 20268-K Executive or director change43
  7. Jun 24, 20268-K Bylaws or fiscal year changed; Shareholder vote44
  8. May 14, 20268-K Results of operations45
  9. Apr 21, 20268-K Executive or director change; Bylaws or fiscal year changed46
  10. Mar 25, 20268-K Results of operations47
  11. Mar 23, 20268-K Entered a material agreement; Unregistered sale of shares; Executive or director change48
  12. Jan 28, 20268-K Other events49
  13. Apr 3, 2024New chief executive Steven A. Ledger becomes CEO12

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202650

When it reported results

  1. Aug 13, 2026Reported quarterly or annual results41
  2. May 14, 2026Reported quarterly or annual results45
  3. Mar 25, 2026Reported quarterly or annual results47
  4. Nov 13, 2025Reported quarterly or annual results51
  5. Aug 11, 2025Reported quarterly or annual results52
  6. May 8, 2025Reported quarterly or annual results53
  7. Mar 24, 2025Reported quarterly or annual results54
  8. Jan 6, 2025Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

359 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 111 major events, 127 insider forms, 30 large holders, 70 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Sep 9, 20268-K EDGAR
  3. Aug 31, 2026EFFECT EDGAR
  4. Aug 27, 20268-K EDGAR
  5. Aug 24, 2026S-1 EDGAR
  6. Aug 13, 20268-K EDGAR
  7. Aug 13, 202610-Q EDGAR
  8. Aug 13, 2026S-8 EDGAR
  9. Jul 23, 20264 EDGAR
  10. Jul 23, 20263 EDGAR
  11. Jul 23, 20268-K EDGAR
  12. Jul 22, 20268-K EDGAR
  13. Jul 22, 2026SCHEDULE 13D/A EDGAR
  14. Jul 9, 20264 EDGAR
  15. Jun 24, 20268-K EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 22, 20264 EDGAR
  18. Jun 22, 20264 EDGAR
  19. Jun 22, 20264 EDGAR
  20. Jun 22, 20264 EDGAR

The 359 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

71 open-market trades by officers, directors and large owners since October 2021: 30 buys and 41 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 7, 2026Brannan Stephen K.DirectorBuy1,000$2.03$2.0KForm 4
Jun 12, 2026WILSON KAREN JDirectorBuy5,000$1.77$8.8KForm 4
Jun 11, 2026WILSON KAREN JDirectorBuy5,100$1.75$8.9KForm 4
May 22, 2026Venkatesan JayDirectorBuy589$1.78$1.0KForm 4
May 22, 2026WILSON KAREN JDirectorBuy10,000$1.93$19.3KForm 4
May 21, 2026WILSON KAREN JDirectorBuy10,000$1.77$17.7KForm 4
May 19, 2026Marshall Richard PeterDirectorBuy12,183$1.65$20.1KForm 4
Mar 23, 2026Moreadith RandallChief Scientific OfficerSale6,500$2.86$18.6KForm 4
Mar 19, 2026Moreadith RandallChief Scientific OfficerSale39,000$2.50$97.5KForm 4
Feb 2, 2026Moreadith RandallChief Scientific OfficerSale6,500$3.03$19.7KForm 4
Jan 28, 2026Moreadith RandallChief Scientific OfficerSale6,500$3.57$23.2KForm 4
Jan 22, 2026Moreadith RandallChief Scientific OfficerSale2,500$2.95$7.4KForm 4
Jan 21, 2026Moreadith RandallChief Scientific OfficerSale2,000$3.00$6.0KForm 4
Jan 20, 2026Moreadith RandallChief Scientific OfficerSale2,000$3.07$6.1KForm 4
Jan 14, 2026Moreadith RandallChief Scientific OfficerSale1,084$2.50$2.7KForm 4
Jan 13, 2026Moreadith RandallChief Scientific OfficerSale5,416$2.50$13.5KForm 4
Jan 8, 2026Moreadith RandallChief Scientific OfficerSale13,000$2.69$35.0KForm 4
Dec 23, 2025Moreadith RandallChief Scientific OfficerSale4,100$2.60$10.7KForm 4
Dec 22, 2025Moreadith RandallChief Scientific OfficerSale5,673$2.67$15.1KForm 4
Dec 16, 2025Moreadith RandallChief Scientific OfficerSale3,227$2.96$9.6KForm 4

All 71 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Steve Ledger66$450.0K$637.5K60
2025Randall MoreadithM.D., Ph.D.$425.0K$563.2K60
2025Srini TenjarlaPh.D.$375.0K$527.4K60
2024Chief Executive Officer$326.2K$3.7M60
2024Chief Technical Operations Officer$171.9K$1.8M60

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 26. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Sio Capital Management, LLC1,000,000$1.9M0.3%No change
Vanguard Capital Management LLC162,198$314.7K0.0%+3,062
Waverly Advisors, LLC67,492$130.9K0.0%No change
Geode Capital Management, LLC51,007$99.0K0.0%−13,966
Keel Point, LLC21,508$41.7K0.0%No change
Northern Trust Corp20,771$40.3K0.0%New
Vanguard Fiduciary Trust Co20,009$38.8K0.0%No change
Avidian Wealth Enterprises, LLC18,800$36.5K0.0%No change
Jane Street Group, LLC15,444$30.0K0.0%−24,209
State Street Corp12,758$24.8K0.0%No change
Caitong International Asset Management Co., Ltd3,744$7.3K0.0%−238
Wells Fargo & Company/mn3,611$7.0K0.0%+5
Tower Research Capital LLC (TRC)2,570$5.0K0.0%+1,727
BlackRock, Inc.2,378$4.6K0.0%−55,886
Osaic Holdings, Inc.2,002$3.9K0.0%+1,001
UBS Group AG1,347$2.6K0.0%+1,342
Barclays PLC545$1.1K0.0%New
Piscataqua Savings Bank28$540.0%No change
Morgan Stanley14$280.0%+6
Albion Financial Group /ut8$160.0%No change
Pacifica Partners Inc.8$150.0%No change
Bnp Paribas Financial Markets2$40.0%No change
Rockefeller Capital Management L.P.2$40.0%No change
Jpmorgan Chase & Co1$20.0%New
Global Retirement Partners, LLC1$20.0%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Serina Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSerina Therapeutics, Inc.1
  • CIK0001708599
  • Employer ID (EIN)82-14368293
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address601 Genome Way, Suite 2001, Huntsville, AL 358061
  • Phone(256) 327-96301
  • Shares outstanding25,400,473 as of Aug 10, 202610
  • Public float$21.8M as of Jun 30, 20253
  • AuditorFrazier & Deeter, LLC, Tampa, Florida PCAOB ID 215; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceJul 10, 20171
  • Filings518 in all: 8-K (153), 4 (143), SC 13D/A (36), 3 (29), 10-Q (23), CORRESP (14), UPLOAD (11), DEF 14A (9)1
    All 42 form types

    DEFA14A (9), 10-K (8), EFFECT (8), S-8 (8), 10-12B/A (5), D (5), PRE 14A (5), S-3 (5), 10-K/A (4), 5 (4), 144 (3), 424B3 (3), 425 (3), SC 13G (3), SC 13G/A (3), PRER14A (2), S-1 (2), S-1/A (2), S-4/A (2), SC 13D (2), 10-12B (1), 3/A (1), 424B5 (1), ARS (1), CERT (1), CT ORDER (1), DEFC14A (1), DEFR14A (1), POS EX (1), S-3/A (1), S-4 (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1), SEC STAFF ACTION (1)

  • Latest filingsAnnual report (10-K) Mar 25, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Apr 27, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareSERNYSE

From the cover page of the 10-K filed Mar 25, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Serina Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 25, 2026: 70 risks under these headings, as written.3

  • being harmed will include harm to our business, reputation, brand, financial condition, results of operations, and prospects. In such event, the market price of our securities could decline, and you could lose all or part of your investment.
  • Risks Related to Our Operating History, Financial Position and Capital Requirements
  • We have a history of operating losses that are expected to continue for the foreseeable future, and we are unable to predict the extent of future losses, or whether we will generate significant revenues or achieve or sustain profitability.
  • We have a limited operating history and expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.
  • We need additional financing to execute our operating plan and continue to operate as a going concern.
  • We have never generated revenue from product sales and may never become profitable.
  • Risks Related to the Development of Our Products
  • Our product candidates are at an early stage of development and may not be successfully developed or commercialized.
  • Preliminary results from our nonclinical studies and clinical trials that we announce or publish from time to time may change as more patient data becomes available and as the data undergoes audit and verification procedures.
  • The FDA or comparable foreign regulatory authorities may disagree with our regulatory plans, and we may fail to obtain regulatory approval of our product candidates.
  • Failure of our technology would significantly harm our business, results of operations, and prospects.
  • We may seek designations under FDA programs designed to facilitate and potentially expedite product candidate development, such as fast track or breakthrough therapy designation. Our product candidates may not receive any such designations or if they do receive such designations they may not lead to faster development or regulatory review or approval and it does not increase the likelihood that our product candidates will receive marketing approval.
The other 60 risks
  • If we are unable to obtain approval via the accelerated approval pathway, we may be required to conduct additional nonclinical studies or clinical trials. Even if we receive accelerated approval from the FDA, the FDA may seek to withdraw accelerated approval.
  • If we apply for orphan drug designation from the FDA, there is no guarantee that we will be able to obtain or maintain this designation, receive this designation for any of our other product candidates, or receive or maintain any corresponding benefits, including periods of exclusivity.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • Any product candidate we advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent our regulatory approval or commercialization or limit our commercial potential.
  • We may form or seek strategic partnerships or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
  • We rely on contract manufacturing organizations to manufacture our nonclinical and clinical pharmaceutical supplies and expect to continue to rely on CMOs to produce commercial supplies of any approved product candidate, and our dependence on CMOs could adversely impact our business.
  • We rely on third parties to conduct some of our nonclinical studies and all of our clinical trials. If these third parties do not meet our deadlines or otherwise conduct the trials as required, our development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for, or commercialize, our product candidates when expected or at all.
  • We rely on other third parties to store and distribute our product candidates for nonclinical studies and clinical trials that we conduct.
  • We may incur substantial product liability or indemnification claims relating to the clinical testing of our product candidates.
  • Risks Related to Our Business, Industry, and Future Commercialization
  • If any product candidate that we successfully develop does not achieve broad market acceptance among physicians, patients, health care payors and the medical community, the revenues that we generate from their sales will be limited.
  • If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.
  • We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.
  • Corporate and academic collaborators may take actions to delay, prevent, or undermine the success of our products.
  • Data provided by collaborators and others upon which we rely that has not been independently verified could turn out to be false, misleading, or incomplete.
  • Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, reimbursement practices, or health care reform initiatives, which would harm our business.
  • Our insurance policies are expensive and protect us only from some business risks, which will leave us exposed to significant uninsured liabilities.
  • Risks Related to Our Intellectual Property
  • Our success is largely based upon our intellectual property and proprietary technologies, and we may be unable to protect and/or enforce our intellectual property.
  • We may be forced to litigate to enforce or defend our intellectual property rights, and/or the intellectual property rights of our licensors.
  • If we or our partners are sued for infringing on the intellectual property rights of third parties, it could be costly and time consuming, and an unfavorable outcome in any such litigation could have a material adverse effect on our business.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • If we do not obtain patent term extension for our drug candidates, our business may be materially harmed.
  • Changes in patent law in the United States and in non U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our technologies and product candidates.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position could be harmed.
  • Third parties may assert that our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.
  • Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.
  • Intellectual property rights do not necessarily address all potential threats.
  • Risks Related to Regulatory and Compliance Matters
  • The FDA regulatory approval process is lengthy, time consuming, and inherently unpredictable, and we may experience significant delays in the clinical development and regulatory approval, if any, of our product candidates.
  • Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements.
  • Additional regulatory burdens and other risks and uncertainties in foreign markets may limit our growth.
  • Health care and other reform legislation may increase the difficulty and cost for us and any collaborators we may have to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.
  • Any additional federal or state health care reform measures could limit the amounts that third-party payors will pay for future health care products and services, and, in turn, could significantly reduce the projected value of certain development projects and reduce our profitability.
  • Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing, and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.
  • Risks Related to Employee and Operations Matters, Managing Growth and Information Technology
  • A pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of product candidates.
  • Our future success depends on our ability to recruit and retain our executive team and key scientists and to attract, retain, and motivate qualified personnel.
  • If we are unable to hire additional qualified personnel, our ability to grow our business may be harmed.
  • We expect to expand our development, regulatory, and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • If we experience material weaknesses in the future or otherwise fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
  • General Risk Factors
  • Unfavorable global economic conditions could adversely affect our business, financial condition, or results of operations.
  • U.S. federal income tax reform could adversely affect our business and financial condition.
  • We face risks associated with increased political uncertainty.
  • Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.
  • Risks Related to the Company
  • We will need to raise additional financing in the future to fund our operations, which may not be available to us on favorable terms or at all.
  • The market price of our common stock is expected to be volatile.
  • We will incur costs and demands upon management as a result of complying with the laws, rules and regulations affecting public companies.
  • If we do not continue to satisfy the NYSE American continued listing requirements, our Common Stock could be delisted from NYSE American
  • Anti-takeover provisions in our governance documents and under Delaware law could make an acquisition of Serina more difficult and may prevent attempts by our stockholders to replace or remove our management.
  • The Amended and Restated Certificate of Incorporation will provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.
  • We do not anticipate paying any cash dividends in the foreseeable future.
  • An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at all.
  • Future sales of shares by existing stockholders could cause our stock price to decline.
  • If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.
  • If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.
  • If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan.
  • We expect to take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our common stock being less attractive to investors.
  • Changes in tax laws may materially adversely affect our business, prospects, financial condition and operating results.
  • Our ability to use net operating loss (NOL) carryforwards and other tax attributes may be limited, including as a result of the Merger.
  • Conflicts of interest may arise from our relationship with Juvenescence, which will own a significant percentage of our common stock as well as warrants to purchase additional shares of our common stock and will be able to substantially influence the Company and exert control over matters subject to stockholder approval.

Legal proceedings

From time to time, we may become involved in legal proceedings or be subject to claims that arise in the ordinary course of business. As of the date of this report, we are not currently a party to any material legal proceedings.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
    SEC EDGAROther events
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60